Clinical Trial Update: Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study [Phase 3]

View source ↗

Summary

This update reports that the Phase 3 extension study of EryDex System in patients with Ataxia Telangiectasia has been terminated, with results posted on 2024-10…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ataxia-telangiectasia

Drugs mentioned

• EryDex System

Snippet

Sponsor: Quince Therapeutics S.p.A. | Conditions: Ataxia Telangiectasia, Genetic Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2024-10-08